GGrantIndex
← Leaderboards

Francis X McCormack

University Of Cincinnati

$13,631,889
Attributed
$15,940,771
Total exposure
20
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,894,062 · 18
FDA$1,046,709 · 1
VA$0 · 1

By mechanism

R01$8,679,471 · 6
U01$3,606,817 · 1
T32$3,171,461 · 1
R13$450,250 · 10
M01$32,772 · 1
I01$0 · 1

Most similar at University Of Cincinnati

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungPathogenesisCellsLung DiseasesGenesLymphangioleiomyomatosisMolecularSignal TransductionInternationalMutationBaseAlveolar MacrophagesWomanGeneticAlveolarTravelFoundationsProteinsProgramsFamilyTuberous SclerosisFda ApprovedResearch PersonnelInfiltration

Grant awards (63)

Novel Mechanisms of Pulmonary Fibrosis$613,518
R01 · FY2025 · HL · contact PI
Pulmonary Development and Disease Pathogenesis Training Program$511,245
T32 · FY2025 · HL
Novel Mechanisms of Pulmonary Fibrosis$614,922
R01 · FY2024 · HL · contact PI
Pulmonary Development and Disease Pathogenesis Training Program$230,990
T32 · FY2024 · HL
Role of Pulmonary Osteoclast-Like Cells in Lung Injury$0
I01 · FY2024 · VA · contact PI
Novel Mechanisms of Pulmonary Fibrosis$643,080
R01 · FY2023 · HL · contact PI
Pulmonary Development and Disease Pathogenesis Training Program$379,406
T32 · FY2023 · HL
Role of Pulmonary Osteoclast-Like Cells in Lung Injury$0
I01 · FY2023 · VA · contact PI
Pulmonary Development and Disease Pathogenesis Training Program$280,349
T32 · FY2022 · HL
Role of Pulmonary Osteoclast-Like Cells in Lung Injury$0
I01 · FY2022 · VA · contact PI
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC$536,596
U01 · FY2021 · HL · contact PI
Pulmonary Epithelial Dynamics and Innate Host Defense$480,973
R01 · FY2021 · HL · contact PI
Pulmonary Development and Disease Pathogenesis Training Program$349,022
T32 · FY2021 · HL
Role of Pulmonary Osteoclast-Like Cells in Lung Injury$0
I01 · FY2021 · VA · contact PI
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC$649,490
U01 · FY2020 · HL · contact PI
Pulmonary Epithelial Dynamics and Innate Host Defense$480,973
R01 · FY2020 · HL · contact PI
Pulmonary Development and Disease Pathogenesis Training Program$343,890
T32 · FY2020 · HL
Pulmonary Epithelial Dynamics and Innate Host Defense$482,196
R01 · FY2019 · HL · contact PI
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC$870,308
U01 · FY2018 · HL · contact PI
Pulmonary Epithelial Dynamics and Innate Host Defense$506,717
R01 · FY2018 · HL · contact PI
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis$394,528
R01 · FY2018 · HL · contact PI
Lung and Cardiovascular Development and Disease Pathogenesis Training Program$71,755
T32 · FY2018 · HL
The 2018 International Rare Lung Diseases Clinical Research Conference$40,000
R13 · FY2018 · HL
2017 LAM Foundation International Lymphangioleiomyomatosis Research Conference$25,000
R13 · FY2018 · HL · contact PI
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC$798,272
U01 · FY2017 · HL · contact PI
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis$394,535
R01 · FY2017 · HL · contact PI
Lung and Cardiovascular Development and Disease Pathogenesis Training Program$183,203
T32 · FY2017 · HL
Lung and Cardiovascular Development and Disease Pathogenesis Training Program$4,549
T32 · FY2017 · HL
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC$752,151
U01 · FY2016 · HL · contact PI
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis$394,735
R01 · FY2016 · HL · contact PI
Lung and Cardiovascular Development and Disease Pathogenesis Training Program$303,926
T32 · FY2016 · HL
2016 LAM Foundation International Lymphangioleiomyomatosis Research Conference$25,000
R13 · FY2016 · HL · contact PI
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis$409,364
R01 · FY2015 · HL · contact PI
Lung and Cardiovascular Development and Disease Pathogenesis Training Program$221,240
T32 · FY2015 · HL
2015 LAM Foundation International Lymphangioleiomyomatosis Conference$25,000
R13 · FY2015 · HL · contact PI
Lung and Cardiovascular Development and Disease Pathogenesis Training Program$291,886
T32 · FY2014 · HL
2014 LAM Foundation International Lymphangioleiomyomatosis Research Conference$25,000
R13 · FY2014 · HL · contact PI
2013 LAM Symposium$18,000
R13 · FY2013 · HL · contact PI
2012 International LAM Research Conference$19,000
R13 · FY2012 · HL · contact PI
FASEB SRC: The Lung Epithelium in Health & Disease$15,000
R13 · FY2012 · HL · contact PI
2011 International LAM Research Conference$25,000
R13 · FY2011 · HL · contact PI
2010 NHLBI/LAM Foundation International Lymphangioleiomyomatosis Research Confere$25,000
R13 · FY2010 · HL · contact PI
PHASE III TRIAL FO SIROLIMUS IN LYMPHANGIOLEIOMYLMATOSIS$348,563
R01 · FY2009 · FD · contact PI
2009 LAM Foundation International Research Conference$25,000
R13 · FY2009 · HL · contact PI
PHASE III TRIAL FO SIROLIMUS IN LYMPHANGIOLEIOMYLMATOSIS$348,845
R01 · FY2008 · FD · contact PI
CLINICAL TRIAL: SIROLIMUS MULTICENTER INTERNATIONAL LYMPHANGIOLEIOMOMATOSIS TRIA$32,772
M01 · FY2008 · RR · contact PI
2008 LAM Foundation International Research Conference$20,000
R13 · FY2008 · HL · contact PI
PHASE III TRIAL FO SIROLIMUS IN LYMPHANGIOLEIOMYLMATOSIS$349,301
R01 · FY2007 · FD · contact PI
The 2007 LAM Foundation Lymphangioleiomyomatosis International Research Conferenc$24,750
R13 · FY2007 · HL · contact PI
Novel Antioxidant Mechanisms of Surfactant Proteins$321,804
R01 · FY2006 · HL · contact PI
Lymphangioleiomyomatosis Research Conference 2006$20,000
R13 · FY2006 · HL · contact PI
Novel Antioxidant Mechanisms of Surfactant Proteins$331,090
R01 · FY2005 · HL
2005 LAM Foundation Lymphangioleiomyomatosis Research$15,000
R13 · FY2005 · HL
Novel Antioxidant Mechanisms of Surfactant Proteins$332,680
R01 · FY2004 · HL
Lymphangioleimyomatosis Research Conference$28,500
R13 · FY2004 · HL
Novel Antioxidant Mechanisms of Surfactant Proteins$334,270
R01 · FY2003 · HL
Lymphangioleiomyomatosis Research Project$25,000
R13 · FY2003 · HL
Novel Antioxidant Mechanisms of Surfactant Proteins$349,110
R01 · FY2002 · HL
SURFACTANT PROTEIN A IN PULMONARY HOST DEFENSE$188,184
R01 · FY2002 · HL
Lymphangioleiomyomatosis Research Project$25,000
R13 · FY2002 · HL
SURFACTANT PROTEIN A IN PULMONARY HOST DEFENSE$182,702
R01 · FY2001 · HL
Lymphangioleiomyomatosis Research Conference$25,000
R13 · FY2001 · HL
SURFACTANT PROTEIN A IN PULMONARY HOST DEFENSE$177,381
R01 · FY2000 · HL